From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure (Part 2/5)

Leong, D. P., McMurray, J. J.V. , Joseph, P. G. and Yusuf, S. (2019) From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure (Part 2/5). Journal of the American College of Cardiology, 74(5), pp. 683-698. (doi:10.1016/j.jacc.2019.04.068) (PMID:31370961)

Full text not currently available from Enlighten.

Abstract

The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease. Recently, the addition of neprilysin inhibition to angiotensin receptor blockade has been shown to be even more effective than angiotensin-converting enzyme inhibition alone in heart failure with reduced ejection fraction, marking an important new milestone in heart failure treatment. This review summarizes the major trials that have informed the clinical role of inhibition of the renin-angiotensin-aldosterone and neprilysin pathways, as well as the limitations of these strategies.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Leong, D. P., McMurray, J. J.V., Joseph, P. G., and Yusuf, S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Journal of the American College of Cardiology
Publisher:Elsevier
ISSN:0735-1097
ISSN (Online):1558-3597
Published Online:29 July 2019

University Staff: Request a correction | Enlighten Editors: Update this record